Background: Tight control of disease activity is the recommended target of therapy for rheumatoid arthritis (RA).
Objectives: To determine the outcome of RA with respect to disease activity and the rate of remission, as measured by the DAS-28, in a real-world inception cohort.
Methods: We conducted an observational cross-sectional study of a single-center real-world inception cohort of 101 consecutive patients being treated for RA in 2009-2010 in a rheumatology outpatient clinic. Patients were managed at the discretion of the attending rheumatologist with the goal of achieving remission. DAS-28 scores were calculated and analyzed by clinical and treatment variables derived from the medical files.
Results: Mean patient age was 58.6 +/- 13.4 years and mean duration of disease 10.7 +/- 7.9years. Disease remission (DAS-28 < 2.6) was achieved in 26.7% of patients and low disease activity (> 2 .6 DAS-28 < 3.2) in 17%. Monotherapy with a conventional disease-modifying anti-rheumatic drug (C-DMARD, 21% of patients at last follow-up) was associated with a significantly lower mean DAS-28 score and C-reactive protein level than combined C-DMARD treatment (79% of patients), and with shorter disease duration than combined treatment with C-DMARDs or C-DMARD(s)+biological DMARD (40% of patients). Rheumatoid factor and anti-cyclic citrullinated peptide positivity had no effect on DAS-28 scores. Time from diagnosis was inversely correlated with DAS-28 scores.
Conclusions: The achievement of low disease activity and remission in a significant portion of our inception cohort of patients with RA suggests that the treat-to-target strategy is feasible and effective in routine clinical practice.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Geosocial Media's Early Warning Capabilities Across US County-Level Political Clusters: Observational Study.
JMIR Infodemiology
January 2025
Salzburg University of Applied Sciences, Puch/Salzburg, Austria.
Background: The novel coronavirus disease (COVID-19) sparked significant health concerns worldwide, prompting policy makers and health care experts to implement nonpharmaceutical public health interventions, such as stay-at-home orders and mask mandates, to slow the spread of the virus. While these interventions proved essential in controlling transmission, they also caused substantial economic and societal costs and should therefore be used strategically, particularly when disease activity is on the rise. In this context, geosocial media posts (posts with an explicit georeference) have been shown to provide a promising tool for anticipating moments of potential health care crises.
View Article and Find Full Text PDFMAPK-CncC Signaling Pathways Regulate the Antitoxic Response to Avermectin-Induced Oxidative Stress in Juvenile Chinese Mitten Crab, .
Environ Sci Technol
January 2025
Key Laboratory of Application of Ecology and Environmental Protection in Plateau Wetland of Sichuan, Xichang University, Xichang 415000 Sichuan Province, China.
This study delves into the adverse effects of AVM, emphasizing oxidative stress induction in the Chinese mitten crab, , and the role of the MAPK-CncC signaling pathway in mediating the antioxidative response. Our findings reveal a dose-dependent impairment in growth performance, alongside occurrence of oxidative stress. The activity of CAT and superoxide dismutase increased significantly in all treatments (0.
View Article and Find Full Text PDFLong-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.
Neurology
February 2025
Department of Neurology and Center of Clinical Neuroscience, First Medical Faculty, General University Hospital and Charles University, Prague, Czech Republic.
Background And Objectives: Patients with multiple sclerosis (MS) may demonstrate better disease control when treatment is initiated on high-efficacy disease-modifying therapies (DMTs) from onset. This subgroup analysis assessed the long-term efficacy and safety profile of the high-efficacy DMT ocrelizumab (OCR) as first-line therapy for early-stage relapsing MS (RMS).
Methods: Post hoc exploratory analyses of efficacy and safety were performed in a subgroup of treatment-naive patients with RMS who received ≥1 dose of OCR in the multicenter OPERA I/II (NCT01247324/NCT01412333) studies.
State-Level Influenza Hospitalization Burden in the United States, 2022-2023.
Am J Public Health
January 2025
Alexia Couture, A. Danielle Iuliano, Ryan Threlkel, Matthew Gilmer, Alissa O'Halloran, Dawud Ujamaa, Matthew Biggerstaff, and Carrie Reed are with the National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA. Howard H. Chang is with the Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA.
To develop a method leveraging hospital-based surveillance to estimate influenza-related hospitalizations by state, age, and month as a means of enhancing current US influenza burden estimation efforts. Using data from the Influenza Hospitalization Surveillance Network (FluSurv-NET), we extrapolated monthly FluSurv-NET hospitalization rates after adjusting for testing practices and diagnostic test sensitivities to non-FluSurv-NET states. We used a Poisson zero-inflated model with an overdispersion parameter within the Bayesian hierarchical framework and accounted for uncertainty and variability between states and across time.
View Article and Find Full Text PDFOral Cyclophosphamide for Patients With Metastatic Castration-Resistant Prostate Cancer in a Scenario of Limited Health Care Resources.
JCO Glob Oncol
January 2025
Genitourinary Medical Oncology Service, Instituto do Câncer do Estado de São Paulo (ICESP), University of São Paulo, São Paulo, Brazil.
Purpose: Prior noncontemporary studies showed that oral cyclophosphamide is an active treatment of metastatic castration-resistant prostate cancer (mCRPC). However, cyclophosphamide is currently underutilized in routine clinical practice given the lack of survival benefit and the emergence of more effective treatments.
Methods: We retrospectively reviewed our institutional database to identify patients with mCRPC treated with cyclophosphamide.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!